Crinetic Pharmaceuticals Awarded $2.2 Million Phase II SBIR Grant

Crinetic Pharmaceuticals (founded and led by SDEE member Scott Struthers) was awarded a $2.2 million dollar Phase II Small Business Innovation Research Grant (SBIR) grant from the NIH to develop novel drugs for the treatment of pituitary tumors. 

 These tumors produce excess growth hormone resulting in a range of symptoms that can include gigantism, excess soft tissue growth, arthritis, hypertension, diabetes, heart failure, kidney failure, and vision loss, a condition called acromegaly.

Crinetics is developing a novel class of small molecule oral somatostatin drugs with improved efficacy called “biased agonists”.Their activity is “biased” towards activating the intracellular signaling pathways that inhibit hormone secretion, while avoiding activation of the pathways that cause desensitization to the actions of drug. Researchers believe that desensitization is a major reason why existing peptide somatostatin drugs so frequently fail to adequately achieve long-term hormonal control. 

Attend SDEE Events Donate | Sponsor SDEE Become a Member

Connect with SDEE

Sign Up for SDEE Newsletter


Morrison Foerster Alexandria


Takeda San Diego BDO logo


Barney and Barney Longfellow Pineapple.gif

SDEE is a nonprofit 501(c)(3) organization founded by local San Diego entrepreneurs
in order to provide a voice for the early stage start-up, to support new entrepreneurs and their companies,
and to sponsor networking and educational events
to help develop the skills necessary to bring funding, business, and jobs to the San Diego area.

© 2015 San Diego Entrepreneurs Exchange. All Rights Reserved